Cargando…

Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response

Drug repurposing is an effective approach to identify active drugs with known toxicity profiles for rare cancers such as ACC. The objective of this study was to determine the anticancer activity of combination treatment for ACC from previously identified candidate agents using quantitative high-thro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nilubol, Naris, Boufraqech, Myriem, Zhang, Lisa, Gaskins, Kelli, Shen, Min, Zhang, Ya-Qin, Gara, Sudheer K., Austin, Christopher P., Kebebew, Electron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152480/ https://www.ncbi.nlm.nih.gov/pubmed/30250647 http://dx.doi.org/10.18632/oncotarget.26050

Ejemplares similares

SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma
por: Tirosh, Amit, et al.
Publicado: (2019)

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2016)

SAT-568 Glutamine Metabolism Is a New Potential Therapeutic Target in Aggressive Thyroid Cancer
por: Patel, Dhaval, et al.
Publicado: (2019)

Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples
por: Gara, Sudheer Kumar, et al.
Publicado: (2015)

Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome
por: Boufraqech, Myriem, et al.
Publicado: (2019)

GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3
por: Gara, Sudheer Kumar, et al.
Publicado: (2020)

Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening
por: Nilubol, Naris, et al.
Publicado: (2012)

New Therapies for Advanced Thyroid Cancer
por: Laha, Diprajan, et al.
Publicado: (2020)

Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
por: Laha, Dipranjan, et al.
Publicado: (2022)

RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma
por: Liu-Chittenden, Yi, et al.
Publicado: (2017)

Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors
por: Gara, Sudheer Kumar, et al.
Publicado: (2018)

68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor
por: Shell, Jasmine, et al.
Publicado: (2018)

Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis
por: Sadowski, Samira M., et al.
Publicado: (2015)

LOX is a novel mitotic spindle-associated protein essential for mitosis
por: Boufraqech, Myriem, et al.
Publicado: (2016)

To the editor
por: Kebebew, Electron, et al.
Publicado: (2017)

Adrenocortical Carcinoma and Synchronous Malignancies
por: Guerrero, Marlon A., et al.
Publicado: (2010)

RF07 | PSUN356 Synergistic Combination of HSP90 and PI3K inhibitors in Adrenocortical Cancer
por: Mishra, Prachi, et al.
Publicado: (2022)

Current Status and Future Targeted Therapy in Adrenocortical Cancer
por: Alyateem, George, et al.
Publicado: (2021)

Bridging the Scientific Gaps to Identify Effective Treatments in Adrenocortical Cancer
por: Michael, Nicholas, et al.
Publicado: (2022)

Adrenocortical carcinoma and pulmonary embolism from tumoral extension
por: Shekhar, Skand, et al.
Publicado: (2019)

ZNF367 Inhibits Cancer Progression and Is Targeted by miR-195
por: Jain, Meenu, et al.
Publicado: (2014)

Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma
por: Liu-Chittenden, Yi, et al.
Publicado: (2015)

Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial
por: Neychev, Vladimir, et al.
Publicado: (2015)

NOP53 as A Candidate Modifier Locus for Familial Non-Medullary Thyroid Cancer
por: Orois, Aida, et al.
Publicado: (2019)

Potent interaction of flavopiridol with MRP1
por: Hooijberg, J H, et al.
Publicado: (1999)

Effect of P-glycoprotein on flavopiridol sensitivity
por: Boerner, S A, et al.
Publicado: (2001)

The Pharmacological Implications of Flavopiridol: An Updated Overview
por: Joshi, Hemant, et al.
Publicado: (2023)

Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III)
por: Thakur, Shilpa, et al.
Publicado: (2019)

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2015)

SUN-115 Distinct DNA Methylation Signature in Neuroendocrine Tumors of Different Primary Sites and Hereditary Predisposition
por: Tirosh, Amit, et al.
Publicado: (2020)

Transgenic models are predictive: the herceptin and flavopiridol experience
por: Schmidt, E
Publicado: (2003)

Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition
por: Ni, Wenjun, et al.
Publicado: (2010)

MiR-886-3p Regulates Cell Proliferation and Migration, and Is Dysregulated in Familial Non-Medullary Thyroid Cancer
por: Xiong, Yin, et al.
Publicado: (2011)

Preclinical Models of Adrenocortical Cancer
por: Sedlack, Andrew J. H., et al.
Publicado: (2023)

Complex effects of flavopiridol on the expression of primary response genes
por: Keskin, Havva, et al.
Publicado: (2012)

Editorial: Molecular Mechanisms in Cancer Endocrinology With Clinical Implications
por: Nilubol, Naris
Publicado: (2022)

The radiation-sensitizing effect of flavopiridol in the esophageal cancer cell line Eca109
por: YAO, YUAN, et al.
Publicado: (2013)

MiR-20a Is Upregulated in Anaplastic Thyroid Cancer and Targets LIMK1
por: Xiong, Yin, et al.
Publicado: (2014)

Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature
por: Neychev, Vladimir, et al.
Publicado: (2017)

Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen
por: Cimica, Velasco, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_a39ksj9ibc6739fh17ugldk0jv